

21st November, 2017

To,

1. National Stock Exchange of India
Exchange Plaza, 5th Floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East)
Mumbai – 400 051
2. BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

**Sub.: Press Release - US FDA approval and launch of Clonidine Hydrochloride
Extended Release Tablets**

(Scrip Codes: NSE – AJANTPHARM EQ & BSE – AJANTPHARM 532331)


Dear Sir/Madam,

We are pleased to inform you that we have received the final approval for Clonidine Hydrochloride Extended Release Tablets from US FDA and the same has been launched in US Market through our wholly owned subsidiary, Ajanta Pharma USA Inc.

Press release issued by us for the same is enclosed for your information and records.

Thanking You,

Yours faithfully,



Gaurang Shah
AVP – Legal & Company Secretary

Encl.: Press Release

Press Release**Ajanta Pharma Announces Approval & Launch of
Clonidine Hydrochloride Extended Release Tablets**

Mumbai, India – (21st November 2017) - Ajanta Pharma Limited, announces today US FDA approval and launch of Clonidine Hydrochloride Extended Release Tablets in the US Market through its wholly owned subsidiary Ajanta Pharma USA Inc. It is a bioequivalent generic version of Kapvay®¹ Tablets and company has launched the product in 0.1mg dosage.

Clonidine Hydrochloride Extended Release Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 39 Abbreviated New Drug Applications (ANDAs) of which it has 22 final ANDA approvals, 2 tentative approvals, and 15 ANDAs under review with US FDA. Till date, it has launched 16 products in the US market.

About Ajanta Pharma

Ajanta Pharma Limited is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,500 employees are engaged in developing, manufacturing, and marketing of quality finished dosages across 30+ countries.

For the financial year ended 31st March, 2017, Ajanta's consolidated revenue stood at Rs. 2,002 cr. (USD 305 million) and net profit stood at Rs. 507 cr. (USD 77 million). For the last 5 years, Ajanta Pharma has posted healthy performance with its consolidated revenue growing at 21% CAGR and net profit at 46% CAGR.

For more information on Ajanta Pharma Ltd., please visit www.ajantapharma.com and for Ajanta Pharma USA Inc., please visit www.ajantapharmausa.com

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

¹ Kapvay® is a registered trademark of Concordia Pharmaceuticals Inc.

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement